# INSMED Inc

Summary updated: 2026-10-02T11:21:54.919735Z
Canonical: https://finbar.com/research/companies/insmed-inc

## Overview

Insmed, Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. Its work spans respiratory, immunology and inflammation, and neuro and other rare-disease areas; the company states its mission is to transform the lives of patients with serious and rare diseases. [1](https://app.finbar.com/go?id=P147554981)[2](https://insmed.com/company/what-guides-us/)

Its commercial portfolio is led by the respiratory medicines ARIKAYCE and BRINSUPRI. ARIKAYCE is commercialized in the United States, Europe and Japan, while Insmed’s offices across the United States, Europe and Japan reflect its international presence. [3](https://app.finbar.com/go?id=P147554714)[4](https://app.finbar.com/go?id=P64072756)[5](https://insmed.com/contact-us/) For the year ended December 31, 2025, the two products generated approximately $606.5 million in combined revenue; in the six months ended June 30, 2026, product revenues, net were approximately $731.5 million. [6](https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update)[7](https://app.finbar.com/go?id=P147554688)
[1](https://app.finbar.com/go?id=P147554981)[2](https://insmed.com/company/what-guides-us/)[3](https://app.finbar.com/go?id=P147554714)[4](https://app.finbar.com/go?id=P64072756)[5](https://insmed.com/contact-us/)[6](https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update)[7](https://app.finbar.com/go?id=P147554688)[2](https://insmed.com/company/what-guides-us/)[5](https://insmed.com/contact-us/)[6](https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update)

## Products & services

Insmed’s marketed products are ARIKAYCE (amikacin liposome inhalation suspension) and BRINSUPRI (brensocatib). ARIKAYCE is an inhaled antibacterial used with other antibiotics for adults with refractory Mycobacterium avium complex (MAC) lung disease and limited or no alternative treatment options in the US. Its market-specific presentations include a 590 mg nebuliser dispersion in Europe and a 590 mg amikacin sulfate inhalation product in Japan; the Lamira nebulizer system is licensed for its delivery. [8](https://app.finbar.com/go?id=P147554983)[9](https://app.finbar.com/go?id=P147554831) BRINSUPRI is an oral, once-daily tablet available in 10 mg and 25 mg strengths for non-cystic fibrosis bronchiectasis in patients aged 12 and older in the US. The European and UK approvals described in the latest report specify the 25 mg tablet for patients with at least two exacerbations or flare-ups in the preceding 12 months. [10](https://app.finbar.com/go?id=P147554984)

The development portfolio includes TPIP, an inhaled dry-powder formulation of treprostinil palmitil being studied for pulmonary hypertension associated with interstitial lung disease, pulmonary arterial hypertension, progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; INS1148, a monoclonal antibody targeting SCF248, initially planned for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and the intrathecally delivered gene therapies INS1201 for Duchenne muscular dystrophy and INS1202 for amyotrophic lateral sclerosis. [11](https://app.finbar.com/go?id=P147554716)[12](https://app.finbar.com/go?id=P147554718)

For the six months ended June 30, 2026, net product revenue was $214.4 million for ARIKAYCE and $517.0 million for BRINSUPRI, out of $731.5 million total. These amounts represent approximately 29% and 71%, respectively, of reported net product revenue; the shares are calculated from the reported figures. [13](https://app.finbar.com/go?id=T16885407)
[8](https://app.finbar.com/go?id=P147554983)[9](https://app.finbar.com/go?id=P147554831)[10](https://app.finbar.com/go?id=P147554984)[11](https://app.finbar.com/go?id=P147554716)[12](https://app.finbar.com/go?id=P147554718)[13](https://app.finbar.com/go?id=T16885407)

## Geographic presence

Insmed is headquartered in Bridgewater, New Jersey, and lists offices in France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom and Japan. Its research laboratories are in New Jersey, New Hampshire, San Diego, California, and Cambridge, UK. The company relies on third parties for clinical-scale and commercial manufacturing rather than owning manufacturing facilities. [5](https://insmed.com/contact-us/)[14](https://annualreport.insmed.com/our-business/)[15](https://app.finbar.com/go?id=P26773796)

Its reported commercial footprint includes the United States, Europe and Japan. As of the 2025 Form 10-K, BRINSUPRI had been approved in the U.S. and EU; submissions in the UK and Japan had been accepted. [16](https://app.finbar.com/go?id=P46191873)

For FY2025, Insmed reported product revenue of $606.4 million: $453.0 million (74.7%) in the U.S. and $153.5 million (25.3%) internationally. For the six months ended June 30, 2026, product revenue was $731.5 million: $648.8 million (88.7%) in the U.S. and $82.6 million (11.3%) internationally. The cited filings report international revenue in aggregate rather than by individual country. [17](https://app.finbar.com/go?id=T8349865)[18](https://app.finbar.com/go?id=T16885391)
[5](https://insmed.com/contact-us/)[14](https://annualreport.insmed.com/our-business/)[15](https://app.finbar.com/go?id=P26773796)[16](https://app.finbar.com/go?id=P46191873)[17](https://app.finbar.com/go?id=T8349865)[18](https://app.finbar.com/go?id=T16885391)[5](https://insmed.com/contact-us/)[14](https://annualreport.insmed.com/our-business/)

## Business segments

Insmed reports **one operating and reportable segment**. The company says its chief operating decision maker manages the business globally and evaluates performance on a consolidated basis; it does not operate separate lines of business for its products or candidates. Accordingly, Respiratory, Immunology & Inflammation, and Neuro & Other Rare are portfolio focus areas—not reported segments. [19](https://app.finbar.com/go?id=P147554923)[16](https://app.finbar.com/go?id=P46191873)

For the six months ended June 30, 2026, product revenue was approximately $731.5 million. As a proxy for contribution—not a segment breakdown—BRINSUPRI represented about 70.7% of product revenue and ARIKAYCE about 29.3%. Revenue by geography was approximately 88.7% U.S. and 11.3% international; these are also revenue disaggregations, not reportable segments. [18](https://app.finbar.com/go?id=T16885391)
[19](https://app.finbar.com/go?id=P147554923)[16](https://app.finbar.com/go?id=P46191873)[18](https://app.finbar.com/go?id=T16885391)

## Company history

Insmed was founded in 1988 as a private company in Charlottesville, Virginia, and became publicly traded in 2000.[20](https://insmed.com/company/)[21](https://investor.insmed.com/faq) In 2010, it combined with Transave, acquiring the company and its inhaled-drug development programs.[22](https://investor.insmed.com/2010-12-02-Insmed-Incorporated-and-Transave-Inc-Announce-Business-Combination) William H. Lewis joined as president and CEO in 2012 and became board chair in 2018.[23](https://investor.insmed.com/2018-11-08-Insmed-Announces-Changes-to-its-Board-of-Directors)

Insmed’s ARIKAYCE received U.S. FDA accelerated approval in 2018, followed by European approval in 2020 and Japanese approval in 2021.[24](https://app.finbar.com/go?id=P60562244) In 2016, the company licensed global development and commercialization rights to brensocatib from AstraZeneca; after subsequent development, the FDA approved it as BRINSUPRI in 2025, followed by European Commission approval in November 2025 and UK approval in February 2026.[25](https://app.finbar.com/go?id=P51962080)[26](https://app.finbar.com/go?id=P147554715) Insmed also expanded its development portfolio through acquisitions of Motus Biosciences and AlgaeneX in 2021, Vertuis Bio in 2023, and Adrestia Therapeutics in 2023.[27](https://app.finbar.com/go?id=P50651473)
[24](https://app.finbar.com/go?id=P60562244)[25](https://app.finbar.com/go?id=P51962080)[26](https://app.finbar.com/go?id=P147554715)[27](https://app.finbar.com/go?id=P50651473)[20](https://insmed.com/company/)[21](https://investor.insmed.com/faq)[22](https://investor.insmed.com/2010-12-02-Insmed-Incorporated-and-Transave-Inc-Announce-Business-Combination)[23](https://investor.insmed.com/2018-11-08-Insmed-Announces-Changes-to-its-Board-of-Directors)

## Sources

1. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554981)
2. [insmed.com](https://insmed.com/company/what-guides-us/)
3. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554714)
4. [INSMED Inc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P64072756)
5. [insmed.com](https://insmed.com/contact-us/)
6. [investor.insmed.com](https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update)
7. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554688)
8. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554983)
9. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554831)
10. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554984)
11. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554716)
12. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554718)
13. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16885407)
14. [annualreport.insmed.com](https://annualreport.insmed.com/our-business/)
15. [INSMED Inc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P26773796)
16. [INSMED Inc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P46191873)
17. [INSMED Inc — Full financial report (2025 Y)](https://app.finbar.com/go?id=T8349865)
18. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16885391)
19. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554923)
20. [insmed.com](https://insmed.com/company/)
21. [investor.insmed.com](https://investor.insmed.com/faq)
22. [investor.insmed.com](https://investor.insmed.com/2010-12-02-Insmed-Incorporated-and-Transave-Inc-Announce-Business-Combination)
23. [investor.insmed.com](https://investor.insmed.com/2018-11-08-Insmed-Announces-Changes-to-its-Board-of-Directors)
24. [INSMED Inc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P60562244)
25. [INSMED Inc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P51962080)
26. [INSMED Inc — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147554715)
27. [INSMED Inc — Full financial report (2025 Y)](https://app.finbar.com/go?id=P50651473)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.